NanoViricides, Inc. (NYSE American: NNVC) announced continued progress advancing its broad-spectrum antiviral drug candidate NV-387 toward a Phase II clinical trial evaluating its oral gummies formulation as a treatment for the current Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo (DRC). The company said its proposed clinical trial has been approved by the DRC Pillar Committee, with preparations underway for ethics and regulatory submissions.
NanoViricides noted that NV-387 is the only orally administered Ebola treatment candidate currently under consideration for clinical trials, offering potential advantages in resource-limited outbreak settings where infusion-based therapies can be difficult to deploy. The company also highlighted the continued expansion of the outbreak, citing 1,561 confirmed cases and 506 deaths in the DRC as of July 6, while emphasizing that no approved treatment or vaccine currently exists for the Bundibugyo strain.
NanoViricides said it believes NV-387’s broad-spectrum antiviral mechanism could provide activity against multiple ebolavirus strains and noted that the same oral gummies formulation has already received approval from DRC regulators for a Phase II trial in Mpox, with product already shipped to the country for that study. This dual progress underscores the potential of NV-387 as a versatile antiviral platform.
The implications for business and technology leaders are significant. If successful, NV-387 could become a critical tool in pandemic preparedness, particularly for outbreaks in regions with limited healthcare infrastructure. For investors, NanoViricides’ ability to navigate regulatory pathways in the DRC and its broad-spectrum approach may signal a promising pipeline. The company’s lead drug candidate, NV-387, is also being developed for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as Mpox and Measles, as detailed on the company’s website at www.nanoviricides.com.
The DRC outbreak’s scale—over 1,500 cases and 500 deaths—highlights the urgent need for effective treatments. NanoViricides’ oral formulation could reduce reliance on intravenous therapies, which require sterile equipment and trained personnel, often scarce in outbreak zones. The company’s technology, based on nanoviricide nanomedicines, aims to target viruses directly while minimizing side effects.
For the broader industry, NanoViricides’ progress may accelerate interest in nanomedicine-based antivirals. The company’s business model relies on licensing technology from TheraCour Pharma, Inc., and it holds exclusive licenses for several viral diseases, including Ebola/Marburg viruses, as noted in the press release. However, the company cautions that drug development is lengthy and capital-intensive, with no assurance of success.
As the outbreak continues, the approval for a Phase II trial in the DRC represents a critical step. The company’s full press release is available at https://ibn.fm/LaNwF. For ongoing updates, investors can visit the company’s newsroom at https://ibn.fm/NNVC.
